Rapid Therapeutic Science Laboratories, Inc. (RTSL) Total Debt (2016 - 2023)
Rapid Therapeutic Science Laboratories' Total Debt history spans 8 years, with the latest figure at $53568.0 for Q2 2023.
- For Q2 2023, Total Debt fell 94.95% year-over-year to $53568.0; the TTM value through Jun 2023 reached $53568.0, down 94.95%, while the annual FY2022 figure was $40647.0, N/A changed from the prior year.
- Total Debt for Q2 2023 was $53568.0 at Rapid Therapeutic Science Laboratories, down from $131700.0 in the prior quarter.
- Across five years, Total Debt topped out at $1.2 million in Q1 2022 and bottomed at $32000.0 in Q1 2020.
- The 5-year median for Total Debt is $440367.5 (2019), against an average of $499383.5.
- The largest YoY upside for Total Debt was 88.67% in 2023 against a maximum downside of 94.95% in 2023.
- A 5-year view of Total Debt shows it stood at $756535.0 in 2019, then plummeted by 94.28% to $43306.0 in 2020, then soared by 2547.46% to $1.1 million in 2021, then crashed by 96.45% to $40647.0 in 2022, then soared by 31.79% to $53568.0 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Total Debt are $53568.0 (Q2 2023), $131700.0 (Q1 2023), and $40647.0 (Q4 2022).